Journal of Literature Pharmacy Sciences

Baikaleinin Apoptozis Üzerine Etkisi
Effect of Baikalein on Apoptosis
Ecenur ÖZKULa, Elvan YILMAZ AKYÜZb
aBahçeşehir Üniversitesi Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü, İstanbul, TÜRKİYE
bSağlık Bilimleri Üniversitesi Hamidiye Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü, İstanbul, TÜRKİYE
J Lit Pharm Sci. 2021;10(1):21-8
doi: 10.5336/pharmsci.2020-76522
Article Language: TR
Full Text
ÖZET
 Kökünde 50'den fazla flavonoid izole edilebilen Scutellaria türleri üzerinde son yıllarda çok sayıda araştırma yapılmaktadır. Fizyolojik aktivitesinden sorumlu en önemli aktif bileşeni ise baikalein olarak bildirilmiştir. Baikaleinin pek çok olumlu etkisinin yanında üzerine en çok çalışılan özelliği antikanserojen özellikleridir. En önemli aktivitesinin ise apoptozis üzerindeki olumlu etkileri olduğu düşünülmektedir. Apoptoz sürecinin planlı ilerlemesi, kanser gelişimi ve ilerlemesinde önemli bir süreçtir. Bu nedenle apoptoz birçok tedavi stratejisinin hedefidir. Baikaleinin ilk mekanizması hücrede proapoptotik, antiapoptotik Bcl-2 ailesi proteinlerinin oranını regüle ederek hücrenin apoptoza eğilimini düzenlemesidir. Radikal oksijen türleri aracılığıyla apoptozisi düzenlemesi ise diğer bir antikanser etki mekanizması olarak değerlendirilmektedir. Tanımlanmış olan diğer mekanizması ise apoptoz, büyüme inhibisyonu ve hücre döngüsünün durdurulmasında yer alan genlerin ekspresyonunu düzenleyen tümör baskılayıcı bir protein olan p53'ü yukarı regüle etmesidir. Kanser gelişimi ile birlikte diyabetin gelişiminde de önemli bir rolü olduğu belirlenen araşidonik asit izoformlarından birisi olan 12-lipoksijenaz üretimini inhibe etmesi ise üzerine çalışılan diğer bir önemli mekanizmasıdır. Bu derleme, baikaleinin kanser tedavisinde kullanılabileceği düşünülen ve üzerine en çok çalışılan etki mekanizmalarını açıklamak amacıyla yazılmıştır. İn vitro ve hayvan deneylerinde gösterilen kanser tedavisi ile ilgili umut vadeden çalışmalar göz önünde bulundurularak, baikalein kullanımının etkilerinin belirleneceği klinik çalışmalara ihtiyaç duyulmaktadır.

Anahtar Kelimeler: Apoptozis; baikalein; flavonoid
ABSTRACT
 In recent years, a lot of research has been studied on Scutellaria species, which can be isolated more than 50 flavonoids at the root. The most important active ingredient responsible for the physiological activity of Scutellaria species has been reported as baicalein. The most studied feature of baicalein is its anti-carcinogenic properties. Its most important activity has been reported as inducing apoptosis. The planned progression of the apoptosis process is an important process in cancer development and progression. Therefore, apoptosis is the target of many treatment strategies. The first mechanism of baicalein is to regulate the cell's tendency to apoptosis by regulating the rate of proapoptotic, antiapoptotic Bcl-2 family proteins in the cell. Regulation of apoptosis through radical oxygen species is considered as another anti-cancer mechanism of action. Another defined mechanism is; Apoptosis upregulates p53, a tumor suppressing protein that regulates the expression of genes involved in growth inhibition and cell cycle arrest. In addition to cancer development, it is another important mechanism studied to inhibit the production of 12-lipoxygenase, which is one of the arachidonic acid isoforms that has an important role in the development of diabetes. The purpose of this review is to explain the most studied mechanisms of action of baicalein that can be used in cancer treatment. Considering the promising studies on cancer treatment in in vitro and animal experiments, clinical studies on the use of baicalein are needed.

Keywords: Apoptosis; baicalein; flavonoid
REFERENCES:
  1. Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev. 2009;35(1):57-68. [Crossref] [PubMed] 
  2. Zhao Q, Chen XY, Martin C. Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants. Sci Bull (Beijing). 2016;61(18):1391-8. [Crossref] [PubMed] [PMC] 
  3. Gao Y, Snyder SA, Smith JN, Chen YC. Anticancer properties of baicalein: a review. Med Chem Res. 2016;25(8):1515-23. [Crossref]  [PubMed]  [PMC] 
  4. Mehendale S, Aung H, Wang CZ, Tong R, Foo A, Xie JT, et al. Scutellaria baicalensis and a constituent flavonoid, baicalein, attenuate ritonavir-induced gastrointestinal side-effects. J Pharm Pharmacol. 2007;59(11):1567-72. [Crossref] [PubMed] [PMC] 
  5. Chen F, Zhuang M, Peng J, Wang X, Huang T, Li S, et al. Baicalein inhibits migration and invasion of gastric cancer cells through suppression of the TGF-β signaling pathway. Mol Med Rep. 2014;10(4):1999-2003. [Crossref] [PubMed] 
  6. Li HL, Zhang S, Wang Y, Liang RR, Li J, An P, et al. Baicalein induces apoptosis via a mitochondrial-dependent caspase activation pathway in T24 bladder cancer cells. Mol Med Rep. 2013;7(1):266-70. [Crossref] [PubMed] 
  7. Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment? Mol Cancer Ther. 2003;2(6):573-80. [PubMed] 
  8. Mis L, Çilingir Yeltekin A. Apoptosis [Apoptosis]. BEÜ Fen Bilimleri Dergisi. 2014;3(1):102-12. [Crossref] 
  9. Lin MG, Liu LP, Li CY, Zhang M, Chen Y, Qin J, et al. Scutellaria extract decreases the proportion of side population cells in a myeloma cell line by down-regulating the expression of ABCG2 protein. Asian Pac J Cancer Prev. 2013;14(12):7179-86. [Crossref] [PubMed] 
  10. Ye F, Wang H, Zhang L, Zou Y, Han H, Huang J. Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression. Tumour Biol. 2015;36(6):4731-40. [Crossref] [PubMed] 
  11. Kim DH, Hossain MA, Kang YJ, Jang JY, Lee YJ, Im E, et al. Baicalein, an active component of Scutellaria baicalensis Georgi, induces apoptosis in human colon cancer cells and prevents AOM/DSS-induced colon cancer in mice. Int J Oncol. 2013;43(5):1652-8. [Crossref] [PubMed] 
  12. Zheng F, Wu J, Zhao S, Luo Q, Tang Q, Yang L, et al. Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells. J Exp Clin Cancer Res. 2015;34(1):41. [Crossref] [PubMed] [PMC] 
  13. Zhang HB, Lu P, Guo QY, Zhang ZH, Meng XY. Baicalein induces apoptosis in esophageal squamous cell carcinoma cells through modulation of the PI3K/Akt pathway. Oncol Lett. 2013;5(2):722-8. [Crossref] [PubMed] [PMC] 
  14. Chen CH, Huang TS, Wong CH, Hong CL, Tsai YH, Liang CC, et al. Synergistic anti-cancer effect of baicalein and silymarin on human hepatoma HepG2 Cells. Food Chem Toxicol. 2009;47(3):638-44. [Crossref] [PubMed] 
  15. Chen YJ, Wu CS, Shieh JJ, Wu JH, Chen HY, Chung TW, et al. Baicalein Triggers mitochondria-mediated apoptosis and enhances the antileukemic effect of vincristine in childhood acute lymphoblastic leukemia ccrf-cem cells. Evid Based Complement Alternat Med. 2013;2013:124747. [Crossref] [PubMed] [PMC] 
  16. Otsuyama KI, Ma Z, Abroun S, Amin J, Shamsasenjan K, Asaoku H, et al. PPARbeta-mediated growth suppression of baicalein and dexamethasone in human myeloma cells. Leukemia. 2007;21:187-90. [Crossref]  [PubMed] 
  17. Phan T, Nguyen VH, A'lincourt Salazar M, Wong P, Diamond DJ, Yim JH, et al. Inhibition of autophagy amplifies baicalein-induced apoptosis in human colorectal cancer. Mol Ther Oncolytics. 2020;19:1-7. [Crossref]  [PubMed]  [PMC] 
  18. Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395-417. [Crossref] [PubMed] 
  19. Pandita A, Singh, AK. The importance of apoptosis in growth and studying the impact of defective cells. Journal of Critical Reviews. 2020;7(1):734-9. [Link] 
  20. Perez-Fidalgo JA. Cell proliferation inhibitors and apoptosis promoters. EJC Suppl. 2020;15:73-6. [Crossref] [PubMed] [PMC] 
  21. Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:150845. Retraction in: Biomed Res Int. 2020;2020:2451249. [Crossref] [PubMed] [PMC] 
  22. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516. [Crossref] [PubMed] [PMC] 
  23. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288(5468):1053-8. [Crossref] [PubMed] 
  24. Narula J, Kharbanda S, Khaw BA. Apoptosis and the heart. Chest. 1997;112(5):1358-62. [Crossref] [PubMed] 
  25. Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment? Mol Cancer Ther. 2003;2(6):573-80. [PubMed] 
  26. Lin YT, Yang JS, Lin HJ, Tan TW, Tang NY, Chaing JH, et al. Baicalein induces apoptosis in SCC-4 human tongue cancer cells via a Ca2+-dependent mitochondrial pathway. In Vivo. 2007;21(6):1053-8. [PubMed] 
  27. Zhang Y, Song L, Cai L, Wei R, Hu H, Jin W. Effects of baicalein on apoptosis, cell cycle arrest, migration and invasion of osteosarcoma cells. Food Chem Toxicol. 2013;53:325-33. [Crossref] [PubMed] 
  28. Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, et al. Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res. 2008;68(21):8918-27. [Crossref] [PubMed] 
  29. Li HL, Zhang S, Wang Y, Liang RR, Li J, An P, et al. Baicalein induces apoptosis via a mitochondrial-dependent caspase activation pathway in T24 bladder cancer cells. Mol Med Rep. 2013;7(1):266-70. [Crossref] [PubMed] 
  30. Mu J, Liu T, Jiang L, Wu X, Cao Y, Li M, et al. The Traditional Chinese medicine baicalein potently inhibits gastric cancer cells. J Cancer. 2016;7(4):453-61. [Crossref] [PubMed] [PMC] 
  31. Zhou QM, Wang S, Zhang H, Lu YY, Wang XF, Motoo Y, et al. The combination of baicalin and baicalein enhances apoptosis via the ERK/p38 MAPK pathway in human breast cancer cells. Acta Pharmacol Sin. 2009;30(12):1648-58. [Crossref] [PubMed] [PMC] 
  32. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004;7(2):97-110. [Crossref] [PubMed] 
  33. Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther. 2008;7(12):1875-84. [Crossref] [PubMed] 
  34. Lee IK, Kang KA, Zhang R, Kim BJ, Kang SS, Hyun JW. Mitochondria protection of baicalein against oxidative damage via induction of manganese superoxide dismutase. Environ Toxicol Pharmacol. 2011;31(1):233-41. [Crossref]  [PubMed] 
  35. Lee JH, Li YC, Ip SW, Hsu SC, Chang NW, Tang NY, et al. The role of Ca2+ in baicalein-induced apoptosis in human breast MDA-MB-231 cancer cells through mitochondria- and caspase-3-dependent pathway. Anticancer Res. 2008;28(3A):1701-11. [PubMed] 
  36. Lin YT, Yang JS, Lin HJ, Tan TW, Tang NY, Chaing JH, et al. Baicalein induces apoptosis in SCC-4 human tongue cancer cells via a Ca2+-dependent mitochondrial pathway. In Vivo. 2007;21(6):1053-8. [PubMed] 
  37. Ye F, Wang H, Zhang L, Zou Y, Han H, Huang J. Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression. Tumour Biol. 2015;36(6):4731-40. [Crossref] [PubMed] 
  38. Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, et al. Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res. 2008;68(21):8918-27. [Crossref] [PubMed] 
  39. Gao J, Zhao H, Hylands PJ, Corcoran O. Secondary metabolite mapping identifies Scutellaria inhibitors of human lung cancer cells. J Pharm Biomed Anal. 2010;53(3):723-8. [Crossref] [PubMed] 
  40. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro. 2006;20(2):187-210. [Crossref] [PubMed] 
  41. Zhou QM, Wang S, Zhang H, Lu YY, Wang XF, Motoo Y, et al. The combination of baicalin and baicalein enhances apoptosis via the ERK/p38 MAPK pathway in human breast cancer cells. Acta Pharmacol Sin. 2009;30(12):1648-58. [Crossref] [PubMed] [PMC] 
  42. Kim SJ, Kim HJ, Kim HR, Lee SH, Cho SD, Choi CS, et al. Antitumor actions of baicalein and wogonin in HT-29 human colorectal cancer cells. Mol Med Rep. 2012;6(6):1443-9. [Crossref] [PubMed] 
  43. Gao J, Morgan WA, Sanchez-Medina A, Corcoran O. The ethanol extract of Scutellaria baicalensis and the active compounds induce cell cycle arrest and apoptosis including upregulation of p53 and Bax in human lung cancer cells. Toxicol Appl Pharmacol. 2011;254(3):221-8. [Crossref] [PubMed] 
  44. Powell WS, Rokach J. Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. Biochim Biophys Acta. 2015;1851(4):340-55. [Crossref] [PubMed] [PMC] 
  45. Wisastra R, Dekker FJ. Inflammation, cancer and oxidative lipoxygenase activity are intimately linked. Cancers (Basel). 2014;6(3):1500-21. [Crossref] [PubMed] [PMC] 
  46. Leung HWC, Yang WH, Lai MY, Lin CJ, Lee HZ. Inhibition of 12-lipoxygenase during baicalein-induced human lung nonsmall carcinoma H460 cell apoptosis. Food and Chemical Toxicology. 2007;45(3):403-11. [Crossref]  [PubMed] 
  47. Tong WG, Ding XZ, Adrian TE. The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun. 2002;296(4):942-8. [Crossref] [PubMed] 
  48. Ding XZ, Kuszynski CA, El-Metwally TH, Adrian TE. Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochem Biophys Res Commun. 1999;266(2):392-9. [Crossref] [PubMed] 
  49. Tong WG, Ding XZ, Witt RC, Adrian TE. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther. 2002;1(11):929-35. [PubMed] 
  50. Xu XM, Yuan GJ, Deng JJ, Guo HT, Xiang M, Yang F, et al. Inhibition of 12-lipoxygenase reduces proliferation and induces apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Hepatobiliary Pancreat Dis Int. 2012;11(2):193-202. [Crossref] [PubMed] 
  51. Ping Z, Jun X, Yan W, Jun Z. Anti-cancer properties of specific Chinese herbal medicines for hepatocellular carcinoma treatment. Eur J Integr Med. 2020:101215. [Crossref] [PubMed] [PMC] 
  52. Wang CZ, Zhang CF, Luo Y, Yao H, Yu C, Chen L, et al. Baicalein, an enteric microbial metabolite, suppresses gut inflammation and cancer progression in ApcMin/+ mice. Clin Transl Oncol. 2020;22(7):1013-22. [Crossref] [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com